UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

OMEROS CORPORATION

(Exact name of registrant as specified in its charter)

Washington		001-34475		91-1663741
(State or other jurisdiction of		(Commission File Number)		(IRS Employer
incorporation)				Identification No.)

1420 Fifth Avenue, Suite 2600
Seattle, Washington 98101
(Address of principal executive offices, including zip code)

(206) 676-5000
(Registrant’s telephone number, including area code)
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

o		Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o		Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o		Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o		Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

Item 1.01 Entry into a Material Definitive Agreement.

     On November 10, 2009, Omeros Corporation entered into the First Amendment of Exclusive Technology Option Agreement with Patobios Limited, Susan R. George, M.D., Brian F. O’Dowd, Ph.D. and U.S. Bank National Association as escrow agent. The amendment amends the Exclusive Technology Option Agreement dated September 4, 2008 between the same parties.

     Pursuant to the original agreement dated September 4, 2008, Omeros was granted the right to purchase Patobios’ assets related to a G protein-coupled receptor, or GPCR, assay technology, comprised of patents and other intellectual property rights, for approximately $10.8 million Canadian dollars, or CAD, of which $7.8 million CAD is payable in cash and $3.0 million CAD is payable in Omeros common stock, subject to adjustment as described below.

     Upon signing the original agreement on September 4, 2008, Omeros paid Patobios a $200,000 CAD cash option fee ($188,000 USD) for the right to test and an exclusive option to purchase the assets during the nine-month period ending June 4, 2009. On June 12, 2009, pursuant to the terms of the original agreement, Omeros paid Patobios an additional $522,000 CAD cash option fee ($471,000 USD) to extend the option period until December 4, 2009, or the Second Option Period. Under the original agreement Omeros had the option to extend this period for one additional six-month period ending June 4, 2010, or the Third Option Period, by paying Patobios an additional cash option fee of $650,000 CAD.

     Under the original agreement, if during an option period Omeros identified a set of molecules, or ligands, that bound to an orphan GPCR using the assay technology, or “de-orphanized” an orphan GPCR, Patobios would have had the option to require Omeros to purchase these assets for the same price Omeros would have been required to pay if it elected to purchase them. Pursuant to the terms of the amendment entered into on November 10, 2009, Patobios has granted Omeros a limited right to de-orphanize orphan GPCRs without triggering Patobios’ right to require Omeros to immediately purchase the assets related to the GPCR assay technology. Omeros retains its exclusive option to purchase the assets from Patobios during the option period for the previously agreed upon purchase price of approximately $10.8 million CAD. Under the amendment, Omeros may now begin screening orphan GPCRs in sets of five using the GPCR assay technology. Should Omeros de-orphanize at least three orphan GPCRs using the assay technology, Omeros may not screen additional sets of orphan GPCRs using the assay technology without Patobios’ consent.

     In addition, upon achievement of the De-Orphanization Milestone by deorphanizing one or more orphan GPCRs:

	(1)		Omeros will be required to pay Patobios a $500,000 CAD de-orphanization milestone payment instead of the previously agreed upon purchase price of approximately $10.8 million CAD — the $500,000 CAD milestone payment would be credited in full against the cash portion of the asset purchase price;
	(2)		Omeros may license, partner or assign therapeutic development and/or commercialization rights associated with up to three de-orphanized orphan GPCRs to third parties, or the Third-Party Licenses, subject to Patobios’ approval of the scope of such Third Party Licenses (Third Party Licenses for any additional de-orphanized orphan GPCRs would require prior approval from Patobios);
	(3)		If Omeros does grant any Third-Party Licenses, then until the agreement with Patobios is terminated or Omeros purchases the assets, whichever occurs first, Omeros shall pay Patobios 60% of any license proceeds received by Omeros from such Third-Party Licenses, subject to certain exceptions, which amounts would be credited in full against the approximately $10.8 million CAD purchase price of the assets;

	(4)		If the agreement with Patobios is terminated prior to Omeros purchasing the assets from Patobios, then any proceeds from Third-Party Licenses will thereafter be shared equally between Patobios and Omeros;
	(5)		Omeros will be required to purchase the assets for the approximately $10.8 million CAD purchase price once the sum of the following items is at least equal to $5.135 million CAD: (a) the amount paid by Omeros to Patobios from the Third-Party Licenses, (b) the amount of any government or non-profit funding received by Omeros specifically allocated for the purchase of the assets and (c) the $500,000 CAD de-orphanization milestone payment;
	(6)		Omeros may no longer terminate the agreement for convenience during an option period for which Omeros has elected to pay an option fee and none of the option fees paid by Omeros will be refundable except in case of a breach of the agreement by Patobios; and
	(7)		Unless Omeros has acquired the assets prior to the close of business on January 4, 2010, the start of Option Period Three, Omeros shall be required to exercise its option for the period and pay the associated fee.

     Pursuant to the amendment, unless the agreement is terminated before December 4, 2009, the Second Option Period shall be extended until January 4, 2010 and Omeros shall pay Patobios an extension fee of $108,333 CAD on or before December 4, 2009. If the Second Option Period is extended, the Third Option Period still ends on June 4, 2010 but the associated option fee is reduced from $650,000 CAD by the amount of the Second Option Period extension fee to $541,667 CAD. In addition, Omeros now has the right to extend the option period for one additional six-month period ending December 4, 2010 by paying Patobios a cash option fee of $500,000 CAD by June 14, 2010.

     The foregoing description of the Exclusive Technology Option Agreement dated September 4, 2008, as amended by the First Amendment of Exclusive Technology Option Agreement dated November 10, 2009, is a summary of the material terms of the agreement between Omeros, Patobios, Susan R. George, M.D., Brian F. O’Dowd, Ph.D. and U.S. Bank National Association as escrow agent. This summary does not purport to be complete and is qualified in its entirety by reference to the original agreement dated September 4, 2008, which is filed as Exhibit 10.42 to the Form S-1/A filed by Omeros on May 15, 2009, and the amendment dated November 10, 2009, which is filed as Exhibit 10.1 to this Current Report on Form 8-K, and are incorporated by reference herein.

Item 9.01 Financial Statements and Exhibits.

          (d) Exhibits.

Exhibit
Number		Description
10.1		First Amendment of Exclusive Technology Option Agreement between the registrant, Patobios Limited, Susan R. George, M.D., Brian F. O’Dowd, Ph.D. and U.S. Bank National Association as escrow agent dated November 10, 2009.

SIGNATURES

     Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: November 12, 2009

EXHIBIT INDEX

Exhibit
Number		Description
10.1		First Amendment of Exclusive Technology Option Agreement between the registrant, Patobios Limited, Susan R. George, M.D., Brian F. O’Dowd, Ph.D. and U.S. Bank National Association as escrow agent dated November 10, 2009.

Exhibit 10.1

FIRST AMENDMENT OF EXCLUSIVE TECHNOLOGY OPTION AGREEMENT

This amendment (this “Amendment”) serves to amend the Exclusive Technology Option Agreement dated September 4, 2008 between Omeros Corporation (“Omeros”), Patobios Limited (“Patobios”), Susan R. George, M.D., Brian F. O’Dowd, Ph.D. and U.S. Bank National Association (the “Agreement”) and is effective as of November 10, 2009. Except as expressly set forth below, capitalized terms used and not redefined in this Amendment have the same meanings given to them in the Agreement.

WHEREAS the Agreement provides that Patobios may exercise the Put Option upon the achievement of the De-Orphanization Milestone;

AND WHEREAS Omeros has advised Patobios that because the De-Orphanization Milestone would trigger the Put Option and the corresponding liability to complete the Acquisition, Omeros has not attempted the surrogate de-orphanization of orphan GPCRs to date;

AND WHEREAS Omeros has advised Patobios that Omeros’ obligations under the Put Option must be conditioned on reasonably sufficient resources being available to Omeros to complete the Acquisition in such circumstances, and has requested that it be able to proceed with the surrogate de-orphanization of orphan GPCRs using the MOCA Technology for purposes of assisting Omeros to determine and demonstrate the validity of the MOCA Technology;

AND WHEREAS Patobios wishes to facilitate Omeros’ achievement of the De-Orphanization Milestone and completion of the Acquisition and for other good and valuable consideration;

NOW THEREFOR Omeros and Patobios hereby agree as follows:

	1.		Permitted Activities.
	1.1		In addition to Omeros’ rights to use the MOCA Technology during the Option Period as set forth in Section 3.1(a) of the Agreement, Omeros shall have the right during the Option Period to attempt to surrogate de-orphanize orphan GPCRs, in sequential sets of five orphan GPCRs per set, to a maximum of three sets and no more, until, and only until, a set is attempted that results in an aggregate for all sets of three orphan GPCRs that have been successfully de-orphanized by Omeros (such activity the “Initial De-Orphanization” and collectively resulting in the “De-Orphanized GPCRs”). For greater certainty, and by way of example, if the first set results in at least three orphan GPCRs having been successfully de-orphanized, Omeros would not have the right to conduct any screening of the second and third sets. Following the screening of each set, Omeros shall provide to Patobios a full and detailed written report on the screening, together with any data reports produced by the subject equipment, and such written report shall include, without limitation, Omeros’ interpretation of the screening results and its reasons therefore, accompanied by a written certification as to accuracy and completeness by Omeros’ Chief Science Officer or Chief Executive Officer, and shall not proceed with the screening of any further sets until Omeros has received a written acknowledgment from Patobios accepting such report (such acknowledgement to be provided within seven days of receipt of such report and not to be unreasonably withheld; provided that Omeros

shall operate in good faith to furnish any additional information within Omeros’ possession regarding the screening and the report should Patobios request such additional information from Omeros within this seven day period, and in the event of such request for additional information Patobios shall have an additional seven days from its receipt of such first requested additional information, provided, however, that Patobios shall not request and Omeros shall not be required to perform additional analysis, to provide its acknowledgement) and authorizing Omeros to proceed with the screening of the next set if three De-Orphanized GPCRs have not been achieved. Patobios understands and agrees that, given that the Initial De-Orphanization will occur in sets of five orphan GPCRs in which all five will be screened simultaneously, it is possible that more than three orphan GPCRs may be de-orphanized (e.g., two GPCRs successfully de-orphanized in the first set of five and two in the second set of five). Omeros will make the selection of the orphan GPCRs to be surrogate de-orphanized during the Initial De-Orphanization with Patobios’ input, and the number of GPCRs screened in any given set may be modified by mutual written agreement. Any successful de-orphanization (i.e., the surrogate de-orphanization of one orphan GPCR meeting the De-Orphanization Milestone criteria set forth in Section 1.14 of the Agreement) in the Initial De-Orphanization will result in the De-Orphanization Milestone to have been achieved and shall trigger Patobios’ Put Notice and sale rights, subject to Omeros’ right to avail itself of the Put Objection Notice procedure provided under the Agreement in such circumstances. Omeros shall notify Patobios in writing immediately in the event the De-Orphanization Milestone is achieved during the Initial De-Orphanization so that Patobios may exercise its Put Notice and sale rights.

	1.2		The provisions of Section 1 of this Amendment shall not change the definition of the De-Orphanization Milestone (for greater certainty, the achievement of one surrogate de-orphanization of one orphan GPCR meeting the De-Orphanization Milestone criteria set forth in Section 1.14 of the Agreement in Omeros’ attempts to complete the Initial De-Orphanization shall result in the De-Orphanization Milestone having been achieved) and, except as expressly set forth in this Amendment, shall not change the parties’ respective rights and obligations when and if the De-Orphanization Milestone is met by Omeros.
	1.3		In the event that the Agreement is terminated for any reason prior to Omeros exercising its option to acquire the MOCA Technology, the Parties’ ownership of Intellectual Property shall be determined in accordance with the Agreement including, without limitation, Sections 3.1, 3.2 and 7.2 of the Agreement, which ownership will not be affected by this Amendment. The parties agree that Omeros shall not be required under any circumstances to convey any equipment, compound libraries, materials or supplies that is purchased or licensed in connection with its performance of the Plan for MOCA Evaluation or the Initial De-Orphanization. For greater certainty, Patobios’ ownership of Intellectual Property shall include, without limitation, the validation path and high through put methodologies developed and used by Omeros in testing and using the MOCA Technology, as well as the data from the arrayscans obtained by Omeros in the process. For greater certainty with respect to the last sentence of Section 7.2 of the

Agreement, if the De-Orphanization Milestone has been achieved and Omeros does not purchase the MOCA Technology prior to the termination of this Agreement, Omeros shall not be entitled to retain or purchase any hits and shall not own any Intellectual Property rights that claim the composition of matter of such compound(s).

	1.4		Upon the De-Orphanization Milestone having been achieved, Omeros shall lose its rights to terminate the Agreement under the provisions of Section 9.1(b).
	1.5		For greater certainty, upon the De-Orphanization Milestone having been achieved by Omeros, Omeros shall communicate such achievement to Patobios immediately and this Agreement shall not terminate before Patobios has had no less than twenty (20) days from being so notified to deliver a Put Notice to Omeros.
	1.6		Upon the De-Orphanization Milestone having been achieved, Omeros shall, within ten (10) days of such event and in accordance with the Payment Instructions, pay to Patobios the sum of $500,000 CAD as an irrevocable and non-refundable deposit on account of the Acquisition Price (the “De-Orphanization Milestone Payment”), which De-Orphanization Milestone Payment shall be credited in full against the cash portion of the Acquisition Price upon the Closing.
	2.		Funding Condition.
	2.1		Patobios’ right to require Omeros to purchase the MOCA Technology upon Omeros’ achievement of the De-Orphanization Milestone and Omeros’ obligation to purchase the MOCA Technology upon receipt of a Put Notice from Patobios, as set forth in Section 3.3 of the Agreement, shall be further conditioned on Omeros’ receipt of at least the Minimum Proceeds (as defined below) during the Option Period. Omeros will be deemed to have received the “Minimum Proceeds” for purposes of this Section 2.1 if the sum of the following amounts is at least equal to five million one hundred thirty five thousand ($5.135MM) CAD: (a) the amount of the Initial Patobios License Proceeds (as defined in Section 4.2 of this Amendment) that have been paid to Patobios by Omeros during the Option Period as provided in Section 4.3 of this Amendment (as converted into CAD on the dates that such proceeds were actually paid to Patobios); (b) the amount of any other funds that Omeros receives from governmental agencies or not-for-profit funding entities during the Option Period that are specifically allocated in the applicable funding document for the payment of the Acquisition Price by Omeros for the MOCA Technology (as converted into CAD as of the dates Omeros actually receives such funds) and (c) the De-Orphanization Milestone Payment. For purposes of clarity, the parties acknowledge that Omeros shall not be required to allocate, set aside or pay to Patobios any funds described in clause (b) of the preceding sentence until Omeros is deemed to have received the Minimum Proceeds. Throughout the term of this Agreement, Omeros shall with reasonable diligence use commercially reasonable efforts to raise the Minimum Proceeds and to source such further capital as may be necessary to enable Omeros to meet its obligations with respect to the Acquisition.

	2.2		Omeros’ right at it sole discretion to purchase the MOCA Technology at any time during the Option Period in accordance with Section 3.2 of the Agreement shall continue and shall not be affected by this Amendment, except for the crediting against the Acquisition Price of the Initial Patobios License Proceeds as set forth in Section 4.3 of this Amendment and the De-Orphanization Milestone Payment as set forth in Section 1.6 of this Amendment.
	2.3		The definition of the Option Fee Credit as defined in Section 1.40 of the Agreement shall remain unchanged prior to receipt by Omeros of a Put Notice from Patobios. If the Closing has not occurred within sixty (60) days following Patobios’ delivery of the Put Notice to Omeros, the Option Fee Credit as defined in Section 1.40 of the Agreement shall be redefined to mean an amount in CAD equal to the product obtained by multiplying (x) the Option Fee for the Option Period in which the Closing occurs, by (y) the quotient obtained by dividing a numerator that is equal to the number of days remaining in such Option Period at the time of the Closing by a denominator that is equal to the total number of days in such Option Period, provided, however, that the length of any delays by Patobios in completing the Closing after receipt of the Exercise Notice shall be added to the numerator.
	3.		Option Periods.
	3.1		If Omeros receives a Put Notice from Patobios in accordance with Section 3.3 of the Agreement during any of Option Period Two, Option Period Three (if entered) or Option Period Four (as defined below, if entered), the corresponding Option Fee Two, Option Fee Three or Option Fee Four (if applicable), respectively, and any subsequent Option Fees paid by Omeros after its receipt of the Put Notice shall thereafter become nonrefundable upon termination of the Agreement for any reason other than breach by Patobios, notwithstanding the provisions of Section 9.2(c) of the Agreement; provided, however, the provisions of this sentence shall not be construed to reduce the Option Fee Credit under Section 1.40 of the Agreement.
	3.2		“Option Period Two” as defined in Section 2.2 of the Agreement shall be extended by one month and redefined to end 5:00 p.m. Seattle time on January 4, 2010. This extension of Option Period Two shall not act to extend Option Period Three, which, if entered into by Omeros as provided in Section 3.3 of this Amendment, shall run through June 4, 2010 unless earlier terminated in accordance with the Agreement and this Amendment.
	3.3		Unless the Agreement has been terminated by either party prior to December 4, 2009 as provided for in Section 9.1 of the Agreement, then by December 4, 2009, Omeros shall pay to Patobios an extension fee (the “Extension Fee”) of one hundred and eight thousand, three hundred and thirty three ($108,333) CAD in consideration for the one month extension of Option Period Two set forth in Section 3.2 of this Amendment.
	3.4		Extension of the Option Period into Option Period Three shall remain discretionary on Omeros’ part unless prior to the end of Option Period Two no Closing has occurred and

			Omeros has achieved the De-Orphanization Milestone, in the event of which occurrences Omeros shall be required to extend the Option Period into Option Period Three. If Omeros extends the Option Period into Option Period Three by providing notice as set forth in Section 2.3 of the Agreement, Omeros shall instead of paying the full Option Fee Three shall pay the difference of the amount of Option Fee Three less the amount of the Extension Fee (i.e., the $650,000 CAD Option Fee Three less the $108,333 CAD Extension Fee = $541,667 CAD).
	3.5		Omeros shall have the option to extend the Option Period beyond Option Period Three for an additional six months to end December 4, 2010 (“Option Period Four”), exercisable by Omeros delivering to Patobios written notice of Omeros’ intent to extend the Option Period by June 4, 2010 and paying to Patobios by June 14, 2010, in accordance with the Payment Instructions, an additional fee of $500,000 CAD (the “Option Fee Four”). During Option Period Four, Omeros, the Founders and Patobios shall have the rights and obligations set forth in Article III of the Agreement and as provided for in this Amendment. The Option Fee Refund provisions of Section 9.2 of the Agreement shall also apply to Option Period Four except as set forth in Section 3.1 of this Amendment.
	3.6		The term “Option Period” under the Agreement shall also include Option Period Four, if Option Fee Four has been paid by Omeros.
	3.7		Clause (a) of the second sentence of the first paragraph of Article III of the Agreement shall be revised to read as follows: “(a) that if within the Option Period (i) an Exercise Notice is provided or (ii) a Put Notice is provided and all other conditions on Omeros’ obligation to purchase the MOCA Technology have been met, then the Option Period shall automatically extend until the earlier of the Closing Date and the termination of this Agreement in accordance with Section 9.1,”.
	3.8		For greater certainty, following the achievement of the De-Orphanization Milestone and if the Closing has not occurred in advance of any remaining Option Periods, the exercise by Omeros of any remaining Option Periods provided for under this Agreement shall become mandatory and any Option Fees paid or payable by Omeros in such circumstances shall be non-refundable, subject to the application of the Option Fee Credit and any available remedies under law or equity for breach of the Agreement by Patobios.
	4.		Licensing of De-Orphanized GPCRs.
	4.1		Omeros and Patobios also agree that during the Option Period Omeros may, in consultation with Patobios, license, partner or assign therapeutic development and/or commercialization rights associated with up to three (and no more) of the De-Orphanized GPCRs to third party(ies) (each a “Third Party License”), subject to the prior written approval by Patobios of the scope, general financial, licensing and/or commercialization terms (as applicable) and target(s) of interest of each proposed Third Party License, such approval not to be unreasonably delayed or conditioned, and that such Third Party License(s) may be granted free of any rights of reversion including in the event that the

Agreement is terminated prior to the Closing. All communications regarding proposed Third Party Licenses shall be considered as Omeros’ Confidential Information under the Agreement. The execution of any Third Party License shall be promptly notified by Omeros to Patobios and Patobios shall be provided with a copy of the executed Third Party License, provided that the copy and content of the Third Party License shall be treated as Omeros’ Confidential Information under the Agreement, and shall additionally be maintained in confidence by Patobios for the full term of the Third Party License except for any disclosure in court by Patobios under a protective order in any legal action by Patobios to enforce the Agreement, and Patobios shall defend, indemnify and hold Omeros harmless for any claims, damages or liability incurred by or threatened against Omeros due to the breach by Patobios of its obligations of confidentiality under the Agreement or this section of this Amendment with respect to the Third Party License. For greater certainty, the exclusions to Confidential Information set out in Section 7.1(b) of the Agreement shall apply to the Omeros Confidential Information noted this section 4.1 of the Amendment. No MOCA Technology shall be transferred directly or indirectly in any such license.

	4.2		Omeros shall pay to Patobios a percentage of any Proceeds (as defined below) from each Third Party License as follows: (a) prior to termination of the Agreement and prior to the Closing, sixty percent (60%) to Patobios in accordance with the Payment Instructions (the “Initial Patobios License Proceeds”) not to exceed any amounts due from Omeros to complete the Acquisition Price; (b) after the Closing (if applicable), zero percent (0%) to Patobios; and (c) after termination of the Agreement (if applicable) in the absence of the Closing, any remaining Proceeds shall be shared equally between Omeros and Patobios for the remainder of the term of the Third Party License. “Proceeds” shall include all monetary compensation collected by Omeros resulting directly from the Third Party License(s) excluding (a) (i) funds received by Omeros in connection with the sale or conveyance of its securities or other financing activities, (ii) funds or other consideration received by Omeros in connection with the merger, sale, acquisition or other conveyance of all of its assets or of assets unrelated to the MOCA Technology, and (iii) funds received by Omeros in payment for the performance of future research or development services not utilizing, prior to the Closing, the MOCA Technology except as mutually agreed between Patobios and Omeros in writing.
	4.3		The full amount of the Initial Patobios License Proceeds paid to Patobios shall be credited against and reduce the Acquisition Price by a corresponding dollar amount, applied first against the cash portion of the Acquisition Price and then if any portion of the Initial Patobios License Proceeds credit remains to the stock portion of the Acquisition Price.
	4.4		The entering by Omeros into one or more Third Party License(s) shall deem the De-Orphanization Milestone to have been achieved and shall trigger Patobios’ Put Notice and sale rights provided under the Agreement and Omeros shall lose its right to use the Put Objection Notice procedure provided for in the Agreement.

	5.		Constraints on Internal Development. Except for the development of product candidates in connection with potential Third Party Licenses as permitted under Section 4 of this Amendment and/or the evaluation of hits as part of the Plan for MOCA Evaluation or the Initial De-Orphanization, prior to the Closing Omeros shall not be permitted to undertake the development of product candidates based on compound hits identified from the surrogate de-orphanization of any De-Orphanized GPCRs. If the Agreement is terminated for any reason prior to the Closing, Omeros shall destroy all hits identified during the Initial De-Orphanization that are not hits generated in connection with De-Orphanized GPCRs that were the subject of Third Party License(s), and shall certify to Patobios that it has completed such destruction within thirty (30) days of termination; provided, however, that Omeros shall not be required to alter or eliminate compound samples from its libraries of compounds.
	6.		Reporting During Option Period. In addition to the obligations set forth in Section 3.1(a) of the Agreement concerning the reporting to Patobios at the end of each defined evaluation or test phase of any study being performed as part of the Plan for MOCA Evaluation, including the results of attempts to achieve the De-Orphanization Milestone, and in addition to the reporting obligations on the part of Omeros provided for in this Amendment, Omeros shall provide Patobios quarterly written reports providing the status of its progress on preparing for and attempting the Initial De-orphanization and shall promptly notify Patobios upon the execution by Omeros of any Third Party Licenses.

	7.		No Other Changes. Except as expressly set forth in this Amendment, all other terms of the Agreement remain in full force and effect unamended.
	8.		Counterparts. This Amendment may be signed in one or more counterparts, all of which shall be considered one and the same agreement and shall become effective when one or more counterparts have been signed by each of the parties and delivered to the other party, it being understood that all parties need not sign the same amendment.

IN WITNESS WHEREOF, Omeros, Patobios, the Founders and the Escrow Agent have caused this Amendment to be signed, all as of the date first written above.

OMEROS CORPORATION						PATOBIOS LIMITED
By:		/s/ Gregory A. Demopulos				By:		/s/ Brian O’Dowd
		Gregory A. Demopulos, M.D.						Name:  Brian O’Dowd
		CEO & Chairman						Title:    CEO
SUSAN R. GEORGE, M.D.						BRIAN F. O’DOWD, PH.D.
/s/ Susan R. George						/s/ Brian O’Dowd